Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A pharmaceutical preparation comprising at least one compound of the general formula (I)

$$Pd(S_2COR)_2$$

wherein R is a straight-chain or branched alkyl residue having 1 – 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 – 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 – 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4-30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6-30 carbon atoms, these residues being optionally substituted by one or several substituents and a pharmaceutically compatible inert carrier or diluent.

2. (Original) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R is a straight chain C1-14 alkyl residue or a C3-14 cycloalkyl residue each.

3. (Previously presented) The pharmaceutical preparation according to claim 1, in the compound of formula (I) wherein R is CH_3CH_2, isopropyl, CH_2CH_2OH, $CH_2CH_2CH_2OH$, or $CH_2(CH_2)_2CH_2OH$.

4. (Previously presented) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I), is Bis(O-cyclohexyl-dithiocarbonato)palladium(II), Bis(O-isopropyl-dithiocarbonato)palladium(II), Bis(O-ethyl-dithiocarbonato)palladium(II), Bis(O-(2-methyl)-butyl-dithiocarbonato)palladium(II), Bis(O-butyl-dithiocarbonato)palladium(II),

Bis(O-hexyl-dithiocarbonato) palladium(II) or Bis(O-methyl)-dithiocarbonato) palladium(II).

5. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deocyspergualine, OKT3 and azathioprine.

6. (Previously presented) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or other cytostatic agents.

7. (Previously presented) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer or anti-autoimmunic agent.

8. (Cancelled)

9. (Currently amended) A method for the treatment of a solid tumor ~~cancerous disease~~ comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 1.

10. (Previously presented) The method according to claim 9, wherein the cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.

11. (Cancelled)

12. (Previously presented) A process for the production of a pharmaceutical preparation according to claim 1, comprising mixing the compound according to formula (I) with a pharmaceutically compatible carrier or diluent.

13. (New) The method according to claim 9 wherein the solid tumor is selected from the group consisting of glioma, a bladder tumor, a lung tumor, melanoma, a breast tumor and an ovarian tumor.

14. (New) A method for the treatment of a solid cancerous disease comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation according to claim 3.

15. (New) The method according to claim 14 wherein solid cancerous disease is selected from the group consisting of glioma, a bladder tumor, a lung tumor, melanoma, a breast tumor and an ovarian tumor.

16. (New) A pharmaceutical preparation comprising at least one compound of the general formula (I)

$$Pd(S_2COR)_2$$

wherein R is a straight chain or branched alkyl residue having 1 to 30 carbon atoms, a straight chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents and a pharmaceutically compatible inert carrier or diluents, wherein said preparation exhibits a higher cytotoxic activity against human cancer cells at pH 6.8 than at pH 7.4.

17. (New) The pharmaceutical preparation according to claim 16, wherein the human cancer cell is selected from SK_MEL 25 or CALU-6.